Ameriprise Financial Inc. Sells 12,882 Shares of ICU Medical, Inc. (ICUI)

Ameriprise Financial Inc. cut its position in ICU Medical, Inc. (NASDAQ:ICUI) by 11.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 96,753 shares of the medical instruments supplier’s stock after selling 12,882 shares during the quarter. Ameriprise Financial Inc. owned approximately 0.48% of ICU Medical worth $17,982,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its holdings in shares of ICU Medical by 55.1% during the third quarter. BNP Paribas Arbitrage SA now owns 7,907 shares of the medical instruments supplier’s stock valued at $1,470,000 after acquiring an additional 2,809 shares in the last quarter. First Trust Advisors LP increased its holdings in shares of ICU Medical by 38.8% during the third quarter. First Trust Advisors LP now owns 11,489 shares of the medical instruments supplier’s stock valued at $2,135,000 after acquiring an additional 3,209 shares in the last quarter. Mutual of America Capital Management LLC acquired a new position in shares of ICU Medical during the third quarter valued at about $836,000. SG Americas Securities LLC increased its holdings in shares of ICU Medical by 207.9% during the third quarter. SG Americas Securities LLC now owns 7,306 shares of the medical instruments supplier’s stock valued at $1,358,000 after acquiring an additional 4,933 shares in the last quarter. Finally, Castleark Management LLC acquired a new position in shares of ICU Medical during the second quarter valued at about $283,000. Institutional investors and hedge funds own 78.15% of the company’s stock.

Shares of ICU Medical, Inc. (ICUI) opened at $215.25 on Wednesday. The company has a market capitalization of $4,235.47, a P/E ratio of 82.51, a P/E/G ratio of 3.38 and a beta of 0.36. ICU Medical, Inc. has a 52-week low of $127.00 and a 52-week high of $218.68. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.65 and a quick ratio of 3.01.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.35. The firm had revenue of $343.20 million for the quarter, compared to analyst estimates of $328.56 million. ICU Medical had a return on equity of 4.81% and a net margin of 2.79%. ICU Medical’s revenue for the quarter was up 253.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.35 earnings per share. equities analysts expect that ICU Medical, Inc. will post 3.95 EPS for the current year.

In related news, Director Joseph R. Saucedo sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $216.06, for a total value of $432,120.00. Following the sale, the director now owns 554,364 shares in the company, valued at $119,775,885.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Robert S. Swinney sold 463 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $181.25, for a total value of $83,918.75. Following the completion of the sale, the director now owns 14,330 shares in the company, valued at approximately $2,597,312.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 119,663 shares of company stock worth $22,887,437. 13.60% of the stock is owned by insiders.

Several equities analysts have recently issued reports on ICUI shares. Zacks Investment Research upgraded shares of ICU Medical from a “sell” rating to a “hold” rating in a report on Monday, September 11th. KeyCorp started coverage on shares of ICU Medical in a report on Tuesday, October 17th. They set a “sector weight” rating on the stock. Finally, BidaskClub upgraded shares of ICU Medical from a “sell” rating to a “hold” rating in a report on Friday, August 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $232.00.

TRADEMARK VIOLATION WARNING: This article was published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.com-unik.info/2017/12/13/ameriprise-financial-inc-sells-12882-shares-of-icu-medical-inc-icui.html.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Institutional Ownership by Quarter for ICU Medical (NASDAQ:ICUI)

What are top analysts saying about ICU Medical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ICU Medical and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit